The Latin America, Middle East and Africa Synthetic Small Molecule API Market would witness market growth of 7.7% CAGR during the forecast period (2022-2028).
Participants, managers, and observers in the bio/pharmaceutical business have generally agreed that the concentration on biologics has made small-molecule medications outdated. Reports of the demise of small-molecule medications are highly overstated, to paraphrase what Mark Twain purportedly said of his circumstance. 60% of all new molecular entities and 82% of all new drug application (NDA) approvals in 2014 were for small-molecule medicines.
Additionally, they make up two-thirds of the pipeline for developing new drugs. Small-molecule medications represent a significant and highly effective part of the bio/pharmaceutical portfolio, even though there is little question that the number and share of large-molecule treatments are rising. Many of the most significant medications released in recent years, including kinase inhibitors like Gleevec and anti-retroviral medications such Sovaldi, are small molecules.
Compared to large molecules, small molecules have several important advantages. At modest doses, often below 10 mg and even in the microgram range, they can be produced to have strong therapeutic benefits. When compared to large-molecule therapies, smaller volumes of API and advanced chemical manufacturing techniques often translate into a cheaper cost of goods. Small molecule analytical technology is highly developed, ensuring quality, effectiveness, and reproducibility.
Research by the WHO indicates that 7% of the world's population is genetically predisposed to hemoglobin diseases such as sickle cell disease and thalassemia. The LAMEA region is experiencing an increase in the need for molecular quality controls as a result of the rising prevalence of such genetic diseases. The government's programs to support clinical research serve as a significant economic engine for the Molecular Quality Control sector. Due to a growth in QC molecular labs, the market for molecular control has grown in the area. In the following years, it is anticipated that in this region, which are both developing, will recover from the consequences of COVID-19 which will surge the growth of the synthetic small molecule API market.
The Brazil market dominated the LAMEA Synthetic Small Molecule API Market by Country in 2021; thereby, achieving a market value of $2,903 million by 2028. The Argentina market would showcase a CAGR of 8.2% during (2022-2028). Additionally, The UAE market would witness a CAGR of 7.4% during (2022-2028).
Based on Manufacturer, the market is segmented into In-house and Outsourced. Based on Application, the market is segmented into Cardiology, Oncology, CNS & Neurology, Endocrinology, Orthopedic, Gastroenterology, Pulmonology, Nephrology, Ophthalmology, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck & Co., Inc., Viatris, Inc., Cipla Limited, Teva Pharmaceuticals Industries Ltd., Sun Pharmaceuticals Industries Ltd., AbbVie, Inc., Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited and Albermale Corporation.
Participants, managers, and observers in the bio/pharmaceutical business have generally agreed that the concentration on biologics has made small-molecule medications outdated. Reports of the demise of small-molecule medications are highly overstated, to paraphrase what Mark Twain purportedly said of his circumstance. 60% of all new molecular entities and 82% of all new drug application (NDA) approvals in 2014 were for small-molecule medicines.
Additionally, they make up two-thirds of the pipeline for developing new drugs. Small-molecule medications represent a significant and highly effective part of the bio/pharmaceutical portfolio, even though there is little question that the number and share of large-molecule treatments are rising. Many of the most significant medications released in recent years, including kinase inhibitors like Gleevec and anti-retroviral medications such Sovaldi, are small molecules.
Compared to large molecules, small molecules have several important advantages. At modest doses, often below 10 mg and even in the microgram range, they can be produced to have strong therapeutic benefits. When compared to large-molecule therapies, smaller volumes of API and advanced chemical manufacturing techniques often translate into a cheaper cost of goods. Small molecule analytical technology is highly developed, ensuring quality, effectiveness, and reproducibility.
Research by the WHO indicates that 7% of the world's population is genetically predisposed to hemoglobin diseases such as sickle cell disease and thalassemia. The LAMEA region is experiencing an increase in the need for molecular quality controls as a result of the rising prevalence of such genetic diseases. The government's programs to support clinical research serve as a significant economic engine for the Molecular Quality Control sector. Due to a growth in QC molecular labs, the market for molecular control has grown in the area. In the following years, it is anticipated that in this region, which are both developing, will recover from the consequences of COVID-19 which will surge the growth of the synthetic small molecule API market.
The Brazil market dominated the LAMEA Synthetic Small Molecule API Market by Country in 2021; thereby, achieving a market value of $2,903 million by 2028. The Argentina market would showcase a CAGR of 8.2% during (2022-2028). Additionally, The UAE market would witness a CAGR of 7.4% during (2022-2028).
Based on Manufacturer, the market is segmented into In-house and Outsourced. Based on Application, the market is segmented into Cardiology, Oncology, CNS & Neurology, Endocrinology, Orthopedic, Gastroenterology, Pulmonology, Nephrology, Ophthalmology, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck & Co., Inc., Viatris, Inc., Cipla Limited, Teva Pharmaceuticals Industries Ltd., Sun Pharmaceuticals Industries Ltd., AbbVie, Inc., Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited and Albermale Corporation.
Scope of the Study
Market Segments Covered in the Report:
By Manufacturer
- In-house
- Outsourced
By Application
- Cardiology
- Oncology
- CNS & Neurology
- Endocrinology
- Orthopedic
- Gastroenterology
- Pulmonology
- Nephrology
- Ophthalmology
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Merck & Co., Inc.
- Viatris, Inc.
- Cipla Limited
- Teva Pharmaceuticals Industries Ltd.
- Sun Pharmaceuticals Industries Ltd.
- AbbVie, Inc.
- Bristol Myers Squibb Company
- Boehringer Ingelheim International GmbH
- Aurobindo Pharma Limited
- Albermale Corporation
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Synthetic Small Molecule API Market by Manufacturer
Chapter 4. LAMEA Synthetic Small Molecule API Market by Application
Chapter 5. LAMEA Synthetic Small Molecule API Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Merck & Co., Inc.
- Viatris, Inc.
- Cipla Limited
- Teva Pharmaceuticals Industries Ltd.
- Sun Pharmaceuticals Industries Ltd.
- AbbVie, Inc.
- Bristol Myers Squibb Company
- Boehringer Ingelheim International GmbH
- Aurobindo Pharma Limited
- Albermale Corporation
Methodology
LOADING...
